Company profile: Ventana
1.1 - Company Overview
Company description
- Provider of tissue-based diagnostic solutions, medical diagnostic systems, and biopsy-based cancer tests. Offers pathology lab instruments, cytology and tissue-based assays, and software for anatomic pathology labs; point-of-care coagulation monitoring; in-vitro diagnostics for clinical chemistry, immunochemistry, PCR, and mass spectrometry; biotech raw materials and QC kits; and non-invasive prenatal screening.
Products and services
- CoaguChek: Point-of-care CoaguChek produces near-patient testing to monitor coagulation in patients on Vitamin K Antagonist medications, supporting ongoing therapy oversight
- Cobas Portfolio: In-vitro cobas Portfolio delivers diagnostic systems spanning clinical chemistry, immunochemistry, PCR, and mass spectrometry to deliver medically relevant answers
- VENTANA Products: Clinical-grade VENTANA Products engineers pathology lab instruments, cytology and tissue-based assays, and software systems that support anatomic pathology labs in delivering biopsy-based cancer diagnostic results
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ventana
Imvax
HQ: United States
Website
- Description: Provider of patient-specific vaccines and immunotherapies for solid tumors, including IGV-001, a personalized treatment for glioblastoma in Phase 2b trials, and preclinical programs IEC-001 (endometrial), IHC-001 (hepatocellular), IUC-001 (urothelial), and IOC-001 (ovarian). Offers the Goldspire platform to capture a tumor’s full antigen signature for developing personalized immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imvax company profile →
PACT Pharma
HQ: United States
Website
- Description: Provider of personalized adoptive T cell therapies designed for the eradication of solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PACT Pharma company profile →
NuView Life Sciences
HQ: United States
Website
- Description: Provider of medical imaging and diagnostic solutions leveraging the NV-VPAC1 peptide to target VPAC1 receptors for PET imaging and theranostic applications. Offers in vitro urine-based diagnostic kits for detecting prostate and bladder cancer, in vivo PET agents for diagnosing breast and prostate cancer, and peptide-guided delivery of isotopes (e.g., Copper-64 for imaging, Copper-67 for treatment).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NuView Life Sciences company profile →
IGM Biosciences
HQ: United States
Website
- Description: Provider of a proprietary, clinical-stage IgM antibody platform developing engineered IgM therapeutics for cancer, autoimmune and inflammatory diseases. Pipeline includes imvotamab (CD20xCD3) for autoimmune diseases, aplitabart (DR5) for colorectal cancer, and IGM-2644 (CD38xCD3) for autoimmune diseases, all in early trials. Also offers an expanded access program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IGM Biosciences company profile →
Indaptus Therapeutics
HQ: United States
Website
- Description: Provider of an immunotherapy platform leveraging attenuated and killed non-pathogenic gram-negative bacteria to activate innate and adaptive immune pathways for anti-tumor and anti-viral activity. Offers Decoy20, a Phase 1 therapeutic candidate using engineered bacteria to stimulate anti-tumor defenses, and an intravenous pipeline targeting cancers and infectious diseases with high unmet needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Indaptus Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ventana
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ventana
2.2 - Growth funds investing in similar companies to Ventana
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ventana
4.2 - Public trading comparable groups for Ventana
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →